Drug Approval | February 01, 2024
Orchid Pharma's Exblifeb granted EMA approval
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
Zidavi is recommended by the Infectious Disease Society of America
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
Subscribe To Our Newsletter & Stay Updated
